Related Experiment Videos
Immunoprophylaxis of respiratory syncytial virus: global experience
1Department of Pediatrics, Section of Infectious Diseases, The University of Colorado School of Medicine and The Children's Hospital, Denver, Colorado, USA. eric.simoes@uchsc.edu
Insights
Respiratory syncytial virus (RSV) is a common childhood infection. Palivizumab, a monoclonal antibody, significantly reduces RSV hospitalizations in high-risk children with few side effects.
Area of Science:
- Pediatrics
- Immunology
- Virology
Background:
- Respiratory syncytial virus (RSV) is a widespread viral infection affecting nearly all children by age two.
- RSV poses significant health risks, including severe illness and mortality, particularly in vulnerable pediatric populations.
- Developing an effective RSV vaccine has been challenging, leading to a focus on alternative prevention strategies.
Purpose of the Study:
- To evaluate the efficacy and safety of palivizumab for preventing RSV-related hospitalizations in high-risk children.
- To review the existing clinical trial and outcomes data supporting palivizumab's use.
Main Methods:
- Palivizumab, a humanized monoclonal antibody, was developed for passive immunization against RSV.
- Clinical trials and real-world outcomes data were analyzed to assess the effectiveness and safety profile of palivizumab.
Main Results:
- Palivizumab demonstrated a significant reduction in RSV-related hospitalizations among high-risk children.
- The treatment exhibited a favorable safety profile with minimal adverse effects.
- Palivizumab has received regulatory approval in numerous countries, including the USA and Europe.
Conclusions:
- Palivizumab is an effective and safe option for passive immunization against RSV in high-risk pediatric populations.
- Ongoing clinical and outcomes data continue to validate the benefits of palivizumab for RSV prevention.
- Passive immunization with palivizumab represents a key strategy for controlling RSV in vulnerable children.
Abstract:
Respiratory syncytial virus (RSV) infects nearly all children by age 2 years, and it causes considerable illness and death in certain high-risk pediatric populations. Historically, treatment for RSV has been symptomatic, and developing a safe and effective vaccine has been a challenge. Therefore, research efforts have turned to passive immunization as the best option to control RSV. Palivizumab, a genetically engineered humanized monoclonal antibody, has been shown to reduce RSV-related hospitalizations significantly, with few adverse effects. It was approved for use in high-risk children in the USA in 1998 and in Europe in 1999; it is now approved for use in more than 45 countries. The efficacy and safety of palivizumab continue to be supported by both clinical trial and outcomes data.